Your request to link to rcsb for Beta-secretase 1

---

• 1FKN: structure of beta-secretase complexed with inhibitor (10.1126/SCIENCE.290.5489.150 )
• 1M4H: crystal structure of beta-secretase complexed with inhibitor om00-3 (10.1021/BI026232N )
• 1SGZ: crystal structure of unbound beta-secretase catalytic domain. (10.1021/BI0498252 )
• 1TQF: crystal structure of human beta secretase complexed with inhibitor 16-oct-07 1tqf 1 title (10.1021/JM049388P )
• 1W50: apo structure of bace (beta secretase) (10.1016/J.JMB.2004.08.018 )
• 1W51: bace (beta secretase) in complex with a nanomolar non- peptidic inhibitor (10.1016/J.JMB.2004.08.018 )
• 1XN2: new substrate binding pockets for beta-secretase. (10.1021/BI048106K )
• 1XN3: crystal structure of beta-secretase bound to a long inhibitor with additional upstream residues. (10.1021/BI048106K )
• 1XS7: crystal structure of a cycloamide-urethane-derived novel inhibitor bound to human brain memapsin 2 (beta-secretase). (10.1016/J.BMCL.2004.10.084 )
• 1YM2: crystal structure of human beta secretase complexed with nvp-aur200 (10.1021/JM050142+ )
• 1YM4: crystal structure of human beta secretase complexed with nvp-amk640 (10.1021/JM050142+ )
• 2B8L: crystal structure of human beta secretase complexed with inhibitor 16-oct-07 2b8l 1 title (10.1016/J.BMCL.2005.10.032 )
• 2B8V: crystal structure of human beta-secretase complexed with l- l000430,469 (10.1016/J.BMCL.2005.10.032 )
• 2F3E: crystal structure of the bace complex with axq093, a macrocyclic inhibitor (10.1021/JM060154A )
• 2F3F: crystal structure of the bace complex with bdf488, a macrocyclic inhibitor (10.1021/JM060154A )
• 2FDP: crystal structure of beta-secretase complexed with an amino- ethylene inhibitor (10.1021/JM0509142 )
• 2G94: crystal structure of beta-secretase bound to a potent and highly selective inhibitor. (10.1021/JA058636J )
• 2HIZ: crystal structure of human beta-secretase (bace) in the presence of an inhibitor (10.1016/J.BMCL.2006.09.092 )
• 2HM1: crystal structure of human beta-secretase (bace) in the presence of an inhibitor (2) (10.1016/J.BMCL.2006.09.091 )
• 2IQG: crystal structure of hydroxyethyl secondary amine-based peptidomimetic inhibitor of human beta-secretase (bace) (10.1021/JM061242Y )
• 2IRZ: crystal structure of human beta-secretase complexed with inhibitor 16-oct-07 2irz 1 remark title (10.1021/JM061046R )
• 2IS0: crystal structure of human beta-secretase complexed with inhibitor 16-oct-07 2is0 1 remark title (10.1021/JM061046R )
• 2NTR: crystal structure of human bace-1 bound to inhibitor (10.1016/J.BMCL.2006.11.003 )
• 2OAH: crystal structure of human beta secretase complexed with inhibitor 16-oct-07 2oah 1 title (10.1016/J.BMCL.2006.12.051 )
• 2OF0: x-ray crystal structure of beta secretase complexed with compound 5 (10.1021/JM0611962 )
• 2OHK: x-ray crystal structure of beta secretase complexed with 1-amino- isoquinoline (10.1021/JM0611962 )
• 2OHL: x-ray crystal structure of beta secretase complexed with 2- aminoquinoline (10.1021/JM0611962 )
• 2OHM: x-ray crystal structure of beta secretase complexed with n~3~- benzylpyridine-2,3-diamine (10.1021/JM0611962 )
• 2OHN: x-ray crystal structure of beta secretase complexed with 4-(4- fluorobenzyl)piperidine (10.1021/JM0611962 )
• 2OHP: x-ray crystal structure of beta secretase complexed with compound 3 (10.1021/JM061197U )
• 2OHQ: x-ray crystal structure of beta secretase complexed with compound 4 (10.1021/JM061197U )
• 2OHR: x-ray crystal structure of beta secretase complexed with compound 6a (10.1021/JM061197U )
• 2OHS: x-ray crystal structure of beta secretase complexed with compound 6b (10.1021/JM061197U )
• 2OHT: x-ray crystal structure of beta secretase complexed with compound 7 (10.1021/JM061197U )
• 2OHU: x-ray crystal structure of beta secretase complexed with compound 8b (10.1021/JM061197U )
• 2P4J: crystal structure of beta-secretase bond to an inhibitor with isophthalamide derivatives at p2-p3 (10.1021/JM061338S )
• 2P83: potent and selective isophthalamide s2 hydroxyethylamine inhibitor of bace1 (10.1016/J.BMCL.2007.03.096 )
• 2P8H: crystal structure of human beta secretase complexed with inhibitor 16-oct-07 2p8h 1 title (10.1002/CMDC.200700038 )
• 2PH6: crystal structure of human beta secretase complexed with inhibitor (10.1016/J.BMCL.2007.04.072 )
• 2PH8: crystal structure of human beta secretase complexed with inhibitor (10.1016/J.BMCL.2007.08.040 )
• 2Q11: structure of bace complexed to compound 1 (10.1021/JM0705408 )
• 2Q15: structure of bace complexed to compound 3a (10.1021/JM0705408 )
• 2QK5: structure of bace1 bound to sch626485 (10.1016/J.BMCL.2007.10.116 )
• 2QMD: structure of bace bound to sch722924 (10.1016/J.BMCL.2007.10.116 )
• 2QMF: structure of bace bound to sch735310 (10.1016/J.BMCL.2007.10.116 )
• 2QMG: structure of bace bound to sch745966 (10.1016/J.BMCL.2007.10.053 )
• 2QP8: structure of bace bound to sch734723 (10.1016/J.BMCL.2007.10.116 )
• 2QU2: bace1 with compound 1 (10.1016/J.BMCL.2007.08.010 )
• 2QU3: bace1 with compound 2 (10.1016/J.BMCL.2007.08.010 )
• 2QZK: crystal structure of human beta secretase complexed with i21 (10.1016/J.BMCL.2007.08.040 )
• 2QZL: crystal structure of human beta secretase complexed with ixs (10.1016/J.BMCL.2006.04.076 )
• 2VA5: x-ray crystal structure of beta secretase complexed with compound 8c (10.1021/JM070829P )
• 2VA6: x-ray crystal structure of beta secretase complexed with compound 24 (10.1021/JM070829P )
• 2VA7: x-ray crystal structure of beta secretase complexed with compound 27 (10.1021/JM070829P )
• 2VIE: human bace-1 in complex with n-((1s,2r)-1-benzyl-2-hydroxy-3-((1,1,5- trimethylhexyl)amino)propyl)-3-(ethylamino)-5-(2-oxopyrrolidin-1-yl) benzamide (10.1016/J.BMCL.2007.12.019 )
• 2VIJ: human bace-1 in complex with 3-(1,1-dioxidotetrahydro-2h-1,2-thiazin- 2-yl)-5-(ethylamino)-n-((1s,2r)-2-hydroxy-1-(phenylmethyl)-3-(1,2,3, 4- tetrahydro-1-naphthalenylamino)propyl)benzamide (10.1016/J.BMCL.2007.12.020 )
• 2VIY: human bace-1 in complex with n-((1s,2r)-3-(((1s)-2-(cyclohexylamino)- 1-methyl-2-oxoethyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-3- (pentylsulfonyl)benzamide (10.1016/J.BMCL.2007.12.017 )
• 2VIZ: human bace-1 in complex with n-((1s,2r)-3-(((1s)-2-(cyclohexylamino)- 1-methyl-2-oxoethyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-3-(2- oxo- 1-pyrrolidinyl)-5-(propyloxy)benzamide (10.1016/J.BMCL.2007.12.017 )
• 2VJ6: human bace-1 in complex with n-((1s,2r)-3-(((1s)-2-(cyclohexylamino)- 1-methyl-2-oxoethyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-3- (ethylamino)-5-(2-oxo-1-pyrrolidinyl)benzamide (10.1016/J.BMCL.2007.12.019 )
• 2VJ7: human bace-1 in complex with 3-(ethylamino)-n-((1s,2r)-2-hydroxy-1- (phenylmethyl)-3-(((3-(trifluoromethyl)phenyl)methyl)amino)propyl)-5- (2-oxo-1-pyrrolidinyl)benzamide (10.1016/J.BMCL.2007.12.019 )
• 2VJ9: human bace-1 in complex with n-((1s,2r)-3-(cyclohexylamino)-2-hydroxy- 1-(phenylmethyl)propyl)-3-(ethylamino)-5-(2-oxo-1-pyrrolidinyl) benzamide (10.1016/J.BMCL.2007.12.019 )
• 2VKM: crystal structure of grl-8234 bound to bace (beta-secretase) (10.1016/J.BMCL.2007.12.028 )
• 2VNM: human bace-1 in complex with 3-(1,1-dioxidotetrahydro-2h-1,2-thiazin- 2-yl)-5-(ethylamino)-n-((1s,2r)-2-hydroxy-1-(phenylmethyl)-3-(((3- (trifluoromethyl)phenyl)methyl)amino)propyl)benzamide (10.1021/JM800138H )
• 2VNN: human bace-1 in complex with 7-ethyl-n-((1s,2r)-2-hydroxy-1- (phenylmethyl)-3-(((3-(trifluoromethyl)phenyl)methyl)amino)propyl)-1- methyl-3,4-dihydro-1h-(1,2,5)thiadiazepino(3,4,5-hi)indole-9- carboxamide 2,2-dioxide (10.1021/JM800138H )
• 2WEZ: human bace-1 in complex with 1-ethyl-n-((1s,2r)-2-hydroxy-3-(((3- (methyloxy)phenyl)methyl)amino)-1-(phenylmethyl)propyl)-4-(2-oxo-1- pyrrolidinyl)-1h-indole-6-carboxamide (10.1016/J.BMCL.2009.03.165 )
• 2WF0: human bace-1 in complex with 4-ethyl-n-((1s,2r)-2-hydroxy-1- (phenylmethyl)-3-(((3-(trifluoromethyl)phenyl)methyl)amino)propyl)-8- (2-oxo-1-pyrrolidinyl)-6-quinolinecarboxamide (10.1016/J.BMCL.2009.03.165 )
• 2WF1: human bace-1 in complex with 7-ethyl-n-((1s,2r)-2-hydroxy-3-(((3- (methyloxy)phenyl(methyl)amino)-1-(phenylmethyl)propyl)-1-methyl-3,4- dihydro-1h-(1,2,5)thiadiazepino(3,4,5-hi)indole-9-carboxamide 2,2- dioxide (10.1016/J.BMCL.2009.03.150 )
• 2WF2: human bace-1 in complex with 8-ethyl-n-((1s,2r)-2-hydroxy-3-(((3- (methyloxy)phenyl)methyl)amino)-1-(phenylmethyl)propyl)-1-methyl-3,4, 7, 8-tetrahydro-1h,6h-(1,2,5)thiadiazepino(5,4,3-de)quinoxaline-10- carboxamide 2,2-dioxide (10.1016/J.BMCL.2009.03.150 )
• 2WF3: human bace-1 in complex with 6-(ethylamino)-n-((1s,2r)-2-hydroxy-3- (((3-(methyloxy)phenyl)methyl)amino)-1-(phenylmethyl)propyl)-1- methyl-1, 3,4,5-tetrahydro-2,1-benzothiazepine-8-carboxamide 2,2- dioxide (10.1016/J.BMCL.2009.03.150 )
• 2WF4: human bace-1 in complex with 6-ethyl-1-methyl-n-((1s)-2-oxo-1- (phenylmethyl)-3-(tetrahydro-2h-pyran-4-ylamino)propyl)-1,3,4,6- tetrahydro(1,2)thiazepino(5,4,3-cd)indole-8-carboxamide 2,2-dioxide (10.1016/J.BMCL.2009.03.149 )
• 2WJO: human bace (beta secretase) in complex with cyclohexanecarboxylic acid (2-(2-am ino-6-phenoxy-4h- quinazolin-3-yl)-2-cyclohexyl-ethyl)-amide (10.1021/JM900818S )
• 2XFI: human bace-1 in complex with n-((1s,2r)-3-(((1s)-2-(cyclohexylamino)- 1-methyl-2-oxoethyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-3- ((methylsulfonyl)(phenyl)amino)benzamide (10.1016/J.BMCL.2010.05.111 )
• 2XFJ: human bace-1 in complex with n-((1s,2r)-3-(((1s)-2-(cyclohexylamino)- 1-methyl-2-oxoethyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-3- (ethylamino)-5-(2-oxo-1-pyrrolidinyl)benzamide (10.1016/J.BMCL.2010.05.111 )
• 2XFK: human bace-1 in complex with n-((1s,2r)-3-(((1s)-2-(cyclohexylamino)- 1-methyl-2-oxoethyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-3- (ethylamino)-5-((methylsulfonyl)(phenyl)amino)benzamide (10.1016/J.BMCL.2010.05.111 )
• 2ZDZ: x-ray structure of bace-1 in complex with compound 3.b.10 (10.1016/J.BMCL.2007.12.010 )
• 2ZE1: x-ray structure of bace-1 in complex with compound 6g (10.1016/J.BMCL.2007.12.010 )
• 2ZHR: crystal structure of bace1 in complex with om99-2 at ph 5.0 (10.1128/MCB.02185-07 )
• 2ZHS: crystal structure of bace1 at ph 4.0 (10.1128/MCB.02185-07 )
• 2ZHT: crystal structure of bace1 at ph 4.5 (10.1128/MCB.02185-07 )
• 2ZHU: crystal structure of bace1 at ph 5.0 (10.1128/MCB.02185-07 )
• 2ZHV: crystal structure of bace1 at ph 7.0 (10.1128/MCB.02185-07 )
• 2ZJH: crystal structure of the human bace1 catalytic domain in complex with n-(1-benzyl-piperidin-4-yl)-4-mercapto-butyramide
• 2ZJI: crystal structure of the human bace1 catalytic domain in complex with n-[1-(2,6-dimethoxy-benzyl)-piperidin-4-yl]-4-mercapto-butyramide
• 2ZJJ: crystal structure of the human bace1 catalytic domain in complex with 4-(4-fluoro-benzyl)-piperazine-2-carboxylic acid (2-mercapto-ethyl)- amide
• 2ZJK: crystal structure of the human bace1 catalytic domain in complex with 4-(4-fluoro-benzyl)-piperazine-2-carboxylic acid(3-mercapto-propyl)-amide
• 2ZJL: crystal structure of the human bace1 catalytic domain in complex with n-[1-(5-bromo-2,3-dimethoxy-benzyl)-piperidin- 4-yl]-4-mercapto-butyramide
• 2ZJM: crystal structure of the human bace1 catalytic domain in complex with n-[1-(5-chloro-2-isopropoxy-3-methoxy-benzyl)- piperidin-4-yl]-2-(4-sulfamoyl-phenoxy)-acetamide
• 2ZJN: crystal structure of the human bace1 catalytic domain in complex with n-[1-(5-chloro-2-isopropoxy-3-methoxy-benzyl)- piperidin-4-yl]-2-(2-methyl-4-sulfamoyl-phenoxy)-acetamide
• 3BRA: bace-1 complexed with compound 1 (10.1016/J.BMCL.2008.01.032 )
• 3BUF: bace-1 complexed with compound 2 (10.1016/J.BMCL.2008.01.032 )
• 3BUG: bace-1 complexed with compound 3 (10.1016/J.BMCL.2008.01.032 )
• 3BUH: bace-1 complexed with compound 4 (10.1016/J.BMCL.2008.01.032 )
• 3CIB: structure of bace bound to sch727596 (10.1016/J.BMCL.2008.04.050 )
• 3CIC: structure of bace bound to sch709583 (10.1016/J.BMCL.2008.04.050 )
• 3CID: structure of bace bound to sch726222 (10.1016/J.BMCL.2008.04.050 )
• 3CKP: crystal structure of bace-1 in complex with inhibitor (10.1016/J.BMCL.2008.03.081 )
• 3CKR: crystal structure of bace-1 in complex with inhibitor (10.1016/J.BMCL.2008.03.081 )
• 3DM6: beta-secretase 1 complexed with statine-based inhibitor (10.1016/J.BMC.2008.09.041 )
• 3DUY: crystal structure of human beta-secretase in complex with nvp-afj144 (10.1016/J.BMCL.2009.01.036 )
• 3DV1: crystal structure of human beta-secretase in complex with nvp-arv999 (10.1016/J.BMCL.2009.01.055 )
• 3DV5: crystal structure of human beta-secretase in complex with nvp-bav544 (10.1016/J.BMCL.2009.01.055 )
• 3EXO: crystal structure of bace1 bound to inhibitor (10.1016/J.BMCL.2008.11.027 )
• 3FKT: crystal structure of human beta secretase complexed with spiropiperdine iminohydantoin inhibitor (10.1021/JM800914N )
• 3H0B: discovery of aminoheterocycles as a novel beta-secretase inhibitor class (10.1016/J.BMCL.2009.04.033 )
• 3HVG: structure of bace (beta secretase) in complex with ev0 (10.1021/BI901061A )
• 3HW1: structure of bace (beta secretase) in complex with ligand ev2 (10.1021/BI901061A )
• 3I25: potent beta-secretase 1 hydroxyethylene inhibitor (10.1016/J.BMC.2009.12.051 )
• 3IGB: bace-1 with compound 3 (10.1021/JM9006752 )
• 3IN3: bace1 with compound 30 (10.1016/J.BMC.2009.12.007 )
• 3IN4: bace1 with compound 38 (10.1016/J.BMC.2009.12.007 )
• 3IND: bace1 with the aminohydantoin compound 29 (10.1021/JM901414E )
• 3INE: bace1 with the aminohydantoin compound s-34 (10.1021/JM901414E )
• 3INF: bace1 with the aminohydantoin compound 37 (10.1021/JM901414E )
• 3INH: bace1 with the aminohydantoin compound r-58 (10.1021/JM901414E )
• 3IVH: design and synthesis of potent bace-1 inhibitors with cellular activity: structure-activity relationship of p1 substituents (10.1016/J.BMCL.2009.09.061 )
• 3IVI: design and synthesis of potent bace-1 inhibitors with cellular activity: structure-activity relationship of p1 substituents (10.1016/J.BMCL.2009.09.061 )
• 3IXJ: crystal structure of beta-secretase 1 in complex with selective beta-secretase 1 inhibitor (10.1021/JM901168F )
• 3IXK: potent beta-secretase 1 inhibitor (10.1016/J.EJMECH.2009.11.013 )
• 3K5C: human bace-1 complex with nb-216 (10.1016/J.BMCL.2009.11.092 )
• 3K5D: crystal structure of bace-1 in complex with ahm178 (10.1016/J.BMCL.2010.01.139 )
• 3K5F: human bace-1 complex with ayh011 (10.1016/J.BMCL.2010.01.139 )
• 3K5G: human bace-1 complex with bjc060 (10.1016/J.BMCL.2010.01.139 )
• 3KMX: structure of bace bound to sch346572 (10.1021/JM901472U )
• 3KMY: structure of bace bound to sch12472 (10.1021/JM901472U )
• 3KN0: structure of bace bound to sch708236 (10.1021/JM901472U )
• 3KYR: bace-1 in complex with a norstatine type inhibitor
• 3L38: bace1 in complex with the aminopyridine compound 44 (10.1016/J.BMCL.2010.02.075 )
• 3L3A: bace-1 with the aminopyridine compound 32 (10.1016/J.BMCL.2010.02.075 )
• 3L58: structure of bace bound to sch589432 (10.1021/JM901408P )
• 3L59: structure of bace bound to sch710413 (10.1021/JM901408P )
• 3L5B: structure of bace bound to sch713601 (10.1021/JM901408P )
• 3L5C: structure of bace bound to sch723871 (10.1021/JM901408P )
• 3L5D: structure of bace bound to sch723873 (10.1021/JM901408P )
• 3L5E: structure of bace bound to sch736062 (10.1021/JM901408P )
• 3L5F: structure of bace bound to sch736201 (10.1021/JM901408P )
• 3LHG: bace1 in complex with the aminohydantoin compound 4g (10.1016/J.BMCL.2010.01.136 )
• 3LNK: structure of bace bound to sch743813 (10.1016/J.BMCL.2010.03.050 )
• 3LPI: structure of bace bound to sch745132 (10.1016/J.BMCL.2010.03.050 )
• 3LPJ: structure of bace bound to sch743641 (10.1016/J.BMCL.2010.03.050 )
• 3LPK: structure of bace bound to sch747123 (10.1016/J.BMCL.2010.03.050 )
• 3MSJ: structure of bace (beta secretase) in complex with inhibitor (10.1016/J.BMCL.2010.06.089 )
• 3MSK: fragment based discovery and optimisation of bace-1 inhibitors (10.1016/J.BMCL.2010.06.089 )
• 3MSL: fragment based discovery and optimisation of bace-1 inhibitors (10.1016/J.BMCL.2010.06.089 )
• 3N4L: bace-1 in complex with eln380842 (10.1016/J.BMCL.2010.06.112 )
• 3NSH: bace-1 in complex with eln475957 (10.1016/J.BMCL.2010.08.070 )
• 3OHF: crystal structure of beta-site app-cleaving enzyme 1 (bace-wt) complex with bms-655295 aka n~3~-((1s,2r)-1- benzyl-2-hydroxy-3-((3- methoxybenzyl)amino)propyl)-n~1~, n~1~-dibutyl-1h-indole-1,3- dicarboxamide (10.1016/J.BMCL.2010.10.079 )
• 3OHH: crystal structure of beta-site app-cleaving enzyme 1 (bace-wt) complex with bms-681889 aka n~1~-butyl-5-cyano- n~3~-((1s,2r)-1-(3,5- difluorobenzyl)-2-hydroxy-3-((3- methoxybenzyl)amino)propyl)-n~1~- methyl-1h-indole-1,3- dicarboxamide (10.1016/J.BMCL.2010.10.079 )
• 3OOZ: bace1 in complex with the aminohydantoin compound 102 (10.1016/J.BMCL.2010.09.029 )
• 3PI5: crystal structure of human beta secretase in complex with bfg356 (10.1016/J.BMCL.2011.02.038 )
• 3QBH: structure based design, synthesis and sar of cyclic hydroxyethylamine (hea) bace-1 inhibitors (10.1016/J.BMCL.2011.02.038 )
• 3QI1: design and synthesis of hydroxyethylamine (hea) bace-1 inhibitors: prime side chromane-containing inhibitors (10.1016/J.BMCL.2013.06.006 )
• 3R1G: structure basis of allosteric inhibition of bace1 by an exosite- binding antibody (10.1126/SCITRANSLMED.3002254 )
• 3R2F: crystal structure of beta-site app-cleaving enzyme 1 (bace-wt) complex with bms-693391 aka (2s)-2-((3r)-3-acetamido-3-isobutyl-2-oxo-1- pyrrolidinyl)-n-((1s,2r)-1-(3,5-difluorobenzyl)-2-hydroxy-2-((2r,4r)- 4-propoxy-2-pyrrolidinyl)ethyl)-4-phenylbutanamide (10.1016/J.BMCL.2011.06.109 )
• 3RSV: structure of bace-1 (beta-secretase) in complex with (r)-3-(2-amino-6- o-tolylquinolin-3-yl)-n-((r)-2,2-dimethyltetrahydro-2h-pyran-4-yl)-2- methylpropanamide (10.1021/JM200544Q )
• 3RSX: structure of bace-1 (beta-secretase) in complex with 6-(thiophen-3- yl)quinolin-2-amine (10.1021/JM200544Q )
• 3RTH: structure of bace-1 (beta-secretase) in complex with 6-(2-(3,3- dimethylbut-1-ynyl)phenyl)quinolin-2-amine (10.1021/JM200544Q )
• 3RTM: structure of bace-1 (beta-secretase) in complex with 3-(2- aminoquinolin-3-yl)-n-cyclohexyl-n-methylpropanamide (10.1021/JM200544Q )
• 3RTN: structure of bace-1 (beta-secretase) in complex with 3-(2-amino-6-o- tolylquinolin-3-yl)-n-cyclohexylpropanamide (10.1021/JM200544Q )
• 3RU1: structure of bace-1 (beta-secretase) in complex with 3-(2- aminoquinolin-3-yl)-n-(cyclohexylmethyl)propanamide (10.1021/JM200544Q )
• 3RVI: structure of bace-1 (beta-secretase) in complex with 2-((2-amino-6-o- tolylquinolin-3-yl)methyl)-n-(cyclohexylmethyl)pentanamide (10.1021/JM200544Q )
• 3S2O: fragment based discovery and optimisation of bace-1 inhibitors (10.1016/J.BMCL.2010.06.089 )
• 3S7L: pyrazolyl and thienyl aminohydantoins as potent bace1 inhibitors (10.1016/J.BMCL.2011.07.057 )
• 3S7M: pyrazolyl and thienyl aminohydantoins as potent bace1 inhibitors (10.1016/J.BMCL.2011.07.057 )
• 3SKF: crystal structure of beta-site app-cleaving enzyme 1 (bace-wt) complex with (2s)-2-((3s)-3-(acetylamino)-3-(butan-2-yl)-2-oxopyrrolidin-1- yl)-n-((2s,3r)-3-hydroxy-4-((3-methoxybenzyl)amino)-1-phenylbutan-2- yl)-4-phenylbutanamide (10.1016/J.BMCL.2011.06.116 )
• 3SKG: crystal structure of beta-site app-cleaving enzyme 1 (bace-wt) complex with (2s)-2-((3r)-3-acetamido-3-isobutyl-2-oxo-1-pyrrolidinyl)-n- ((1s,2r)-1-(3,5-difluorobenzyl)-2-hydroxy-2-(1,2,3,4-tetrahydro-3- isoquinolinyl)ethyl)-4-phenylbutanamide (10.1016/J.BMCL.2011.06.116 )
• 3TPJ: apo structure of bace1 (10.1107/S0907444911047251 )
• 3TPL: apo structure of bace1 (10.1107/S0907444911047251 )
• 3TPP: crystal structure of bace1 complexed with an inhibitor (10.1107/S0907444911047251 )
• 3TPR: crystal structure of bace1 complexed with an inhibitor (10.1107/S0907444911047251 )
• 3U6A: rational design and synthesis of aminopiperazinones as beta secretase (bace) inhibitors (10.1016/J.BMCL.2011.10.050 )
• 3UDH: crystal structure of bace with compound 1 (10.1021/JM201715D )
• 3UDJ: crystal structure of bace with compound 5 (10.1021/JM201715D )
• 3UDK: crystal structure of bace with compound 6 (10.1021/JM201715D )
• 3UDM: crystal structure of bace with compound 8 (10.1021/JM201715D )
• 3UDN: crystal structure of bace with compound 9 (10.1021/JM201715D )
• 3UDP: crystal structure of bace with compound 12 (10.1021/JM201715D )
• 3UDQ: crystal structure of bace with compound 13 (10.1021/JM201715D )
• 3UDR: crystal structure of bace with compound 14 (10.1021/JM201715D )
• 3UDY: crystal structure of bace with compound 11 (10.1021/JM201715D )
• 3UFL: discovery of pyrrolidine-based b-secretase inhibitors: lead advancement through conformational design for maintenance of ligand binding efficiency (10.1016/J.BMCL.2011.11.024 )
• 3UQP: crystal structure of bace1 with its inhibitor (10.1021/JM301630S )
• 3UQR: crystal structure of bace1 with its inhibitor (10.1021/JM301630S )
• 3UQU: crystal structure of bace1 with its inhibitor
• 3UQW: crystal structure of bace1 with its inhibitor
• 3UQX: crystal structure of bace1 with its inhibitor
• 3VEU: crystal structure of human beta secretase in complex with nvp-avi326 (10.1021/JM300069Y )
• 3VF3: crystal structure of human beta secretase in complex with nvp-bqq711 (10.1021/JM300069Y )
• 3VG1: crystal structure of human beta secretase in complex with nvp-bur436, derived from a soaking experiment (10.1021/JM300069Y )
• 3VV6: crystal structure of beta secetase in complex with 2-amino-3-methyl-6- ((1s, 2r)-2-phenylcyclopropyl)pyrimidin-4(3h)-one (10.1021/JM3011405 )
• 3VV7: crystal structure of beta secetase in complex with 2-amino-6-((1s,2r)- 2-(3'-methoxybiphenyl-3-yl)cyclopropyl)-3-methylpyrimidin-4(3h)-one (10.1021/JM3011405 )
• 3VV8: crystal structure of beta secetase in complex with 2-amino-3-methyl-6- ((1s,2r)-2-(3'-methylbiphenyl-4-yl)cyclopropyl)pyrimidin-4(3h)-one (10.1021/JM3011405 )
• 3WB4: crystal structure of beta secetase in complex with 2-amino-3,6- dimethyl-6-(2-phenylethyl)-3,4,5,6-tetrahydropyrimidin-4-one (10.1016/J.BMC.2013.08.036 )
• 3WB5: crystal structure of beta secetase in complex with (6s)-2-amino-3,6- dimethyl-6-[(1r,2r)-2-phenylcyclopropyl]-3,4,5,6-tetrahydropyrimidin- 4-one (10.1016/J.BMC.2013.08.036 )
• 3ZMG: crystal structure of bace-1 in complex with chemical ligand (10.1021/JM400225M )
• 3ZOV: crystal structure of bace-1 in complex with chemical ligand (10.1107/S0907444913006574 )
• 4ACU: aminoimidazoles as bace-1 inhibitors. x-ray crystal structure of beta secretase complexed with compound 14 (10.1016/J.BMCL.2012.01.079 )
• 4ACX: aminoimidazoles as bace-1 inhibitors. x-ray crystal structure of beta secretase complexed with compound 23 (10.1016/J.BMCL.2012.01.079 )
• 4AZY: design and synthesis of bace1 inhibitors with in vivo brain reduction of beta-amyloid peptides (compound 10) (10.1021/JM3009025 )
• 4B00: design and synthesis of bace1 inhibitors with in vivo brain reduction of beta-amyloid peptides (compound (r)-41) (10.1021/JM3009025 )
• 4B05: preclinical characterization of azd3839, a novel clinical candidate bace1 inhibitor for the treatment of alzheimer disease (10.1074/JBC.M112.409110 )
• 4B0Q: lead generation of bace1 inhibitors by coupling non-amidine new warheads to a known binding scaffold
• 4B1C: new aminoimidazoles as bace-1 inhibitors: from rational design to ab- lowering in brain (10.1021/JM300991N )
• 4B1D: new aminoimidazoles as bace-1 inhibitors: from rational design to ab- lowering in brain (10.1021/JM300991N )
• 4B1E: new aminoimidazoles as bace-1 inhibitors: from rational design to ab- lowering in brain (10.1021/JM300991N )
• 4B70: aminoimidazoles as bace-1 inhibitors: from de novo design to ab-lowering in brain (10.1021/JM3011349 )
• 4B72: aminoimidazoles as bace-1 inhibitors: from de novo design to ab-lowering in brain (10.1021/JM3011349 )
• 4B77: aminoimidazoles as bace-1 inhibitors: from de novo design to ab-lowering in brain (10.1021/JM3011349 )
• 4B78: aminoimidazoles as bace-1 inhibitors: from de novo design to ab-lowering in brain (10.1021/JM3011349 )
• 4BEK: crystal structure of bace-1 in complex with chemical ligand (10.1016/J.BMCL.2013.05.003 )
• 4BFD: crystal structure of bace-1 in complex with chemical ligand (10.1016/J.BMCL.2013.05.003 )
• 4D83: crystal structure of human beta secretase in complex with nvp-bur436, derived from a co-crystallization experiment (10.1021/JM300069Y )
• 4D85: crystal structure of human beta secretase in complex with nvp-bvi151 (10.1021/JM300069Y )
• 4D88: crystal structure of human beta secretase in complex with nvp-bxq490 (10.1021/JM300069Y )
• 4D89: crystal structure of human beta secretase in complex with nvp-bxd552, derived from a soaking experiment (10.1021/JM300069Y )
• 4D8C: crystal structure of human beta secretase in complex with nvp-bxd552, derived from a co-crystallization experiment (10.1021/JM300069Y )
• 4DH6: structure of bace-1 (beta-secretase) in complex with (2r)-n-((2s,3r)- 1-(benzo[d][1,3]dioxol-5-yl)-3-hydroxy-4-((s)-6'-neopentyl-3',4'- dihydrospiro[cyclobutane-1,2'-pyrano[2,3-b]pyridine]-4'-ylamino) butan-2-yl)-2-methoxypropanamide (10.1021/JM300119P )
• 4DI2: crystal structure of bace1 in complex with hydroxyethylamine inhibitor 37 (10.1021/JM300118S )
• 4DJU: structure of bace bound to 2-imino-3-methyl-5,5-diphenylimidazolidin- 4-one (10.1016/J.BMCL.2012.02.013 )
• 4DJV: structure of bace bound to 2-imino-5-(3'-methoxy-[1,1'-biphenyl]-3- yl)-3-methyl-5-phenylimidazolidin-4-one (10.1016/J.BMCL.2012.02.013 )
• 4DJW: structure of bace bound to 2-imino-3-methyl-5-phenyl-5-(3-(pyridin-3- yl)phenyl)imidazolidin-4-one (10.1016/J.BMCL.2012.02.013 )
• 4DJX: structure of bace bound to 5-(3-(5-chloropyridin-3-yl)phenyl)-5- cyclopropyl-2-imino-3-methylimidazolidin-4-one (10.1016/J.BMCL.2012.02.013 )
• 4DJY: structure of bace bound to (r)-5-cyclopropyl-2-imino-3-methyl-5-(3-(5- (prop-1-yn-1-yl)pyridin-3-yl)phenyl)imidazolidin-4-one (10.1016/J.BMCL.2012.02.013 )
• 4DPF: bace-1 in complex with a hea-macrocyclic type inhibitor (10.1016/J.BMC.2012.05.039 )
• 4DPI: bace-1 in complex with hea-macrocyclic inhibitor, mv078512 (10.1016/J.BMC.2012.05.039 )
• 4DUS: structure of bace-1 (beta-secretase) in complex with n-((2s,3r)-1-(4- fluorophenyl)-3-hydroxy-4-((6'-neopentyl-3',4'- dihydrospiro[cyclobutane-1,2'-pyrano[2,3-b]pyridin]-4'-yl)amino) butan-2-yl)acetamide (10.1021/ML3000148 )
• 4DV9: crystal structure of bace1 with its inhibitor (10.1021/JM301630S )
• 4DVF: crystal structure of bace1 with its inhibitor (10.1021/JM301630S )
• 4EWO: design and synthesis of potent hydroxyethylamine (hea) bace-1 inhibitors (10.1016/J.BMCL.2012.08.097 )
• 4EXG: design and synthesis of potent hydroxyethylamine (hea) bace-1 inhibitors (10.1016/J.BMCL.2012.08.097 )
• 4FCO: crystal structure of bace1 with its inhibitor
• 4FGX: crystal structure of bace1 with novel inhibitor (10.1021/JM301630S )
• 4FM7: crystal structure of bace with compound 14g (10.1021/JM3009426 )
• 4FM8: crystal structure of bace with compound 12a (10.1021/JM3009426 )
• 4FRI: crystal structure of bace1 in complex with biarylspiro aminooxazoline 6 (10.1021/JM300598E )
• 4FRJ: crystal structure of bace1 in complex with aminooxazoline xanthene 9l (10.1021/JM300598E )
• 4FRK: crystal structure of bace1 in complex with aminooxazoline xanthene 11a (10.1021/JM300598E )
• 4FRS: structure of bace in complex with (s)-4-(3-chloro-5-(5-(prop-1-yn-1- yl)pyridin-3-yl)thiophen-2-yl)-1,4-dimethyl-6-oxotetrahydropyrimidin- 2(1h)-iminium (10.1021/ML3001165 )
• 4FS4: structure of bace bound to (s)-4-(3'-methoxy-[1,1'-biphenyl]-3-yl)-1, 4-dimethyl-6-oxotetrahydropyrimidin-2(1h)-iminium (10.1021/ML3000148 )
• 4FSE: crystal structure of beta-site app-cleaving enzyme 1 (bace-wt) complex with n-(n-(4-amino-3,5- dichlorobenzyl)carbamimidoyl)-3-(4- methoxyphenyl)-5- methyl-4-isothiazolecarboxamide (10.1021/JM300931Y )
• 4FSL: crystal structure of beta-site app-cleaving enzyme 1 (bace-db-mut) complex with n-(n-(4- acetamido-3-chloro-5-methylbenzyl) carbamimidoyl)-3-(4- methoxyphenyl)-5-methyl-4-isothiazolecarboxamide (10.1021/JM300931Y )
• 4GID: structure of beta-secretase complexed with inhibitor (10.1021/JM3008823 )
• 4GMI: bace-1 in complex with hea-type macrocyclic inhibitor, mv078571
• 4H1E: structure of bace-1 bound to (7ar)-6-benzoyl-7a-(4-(3-cyanophenyl) thiophen-2-yl)-3-methyl-4-oxohexahydro-1h-pyrrolo[3,4-d]pyrimidin- 2(3h)-iminium (10.1021/JM301039C )
• 4H3F: structure of bace bound to 3-(5-((7ar)-2-imino-6-(6-methoxypyridin-2- yl)-3-methyl-4-oxooctahydro-1h-pyrrolo[3,4-d]pyrimidin-7a-yl) thiophen-3-yl)benzonitrile (10.1021/JM301039C )
• 4H3G: structure of bace bound to 2-((7ar)-7a-(4-(3-cyanophenyl)thiophen-2- yl)-2-imino-3-methyl-4-oxohexahydro-1h-pyrrolo[3,4-d]pyrimidin-6(2h)- yl)nicotinonitrile (10.1021/JM301039C )
• 4H3I: structure of bace bound to 3-(5-((7ar)-2-imino-6-(3-methoxypyridin-2- yl)-3-methyl-4-oxooctahydro-1h-pyrrolo[3,4-d]pyrimidin-7a-yl) thiophen-3-yl)benzonitrile (10.1021/JM301039C )
• 4H3J: structure of bace bound to 2-fluoro-5-(5-(2-imino-3-methyl-4-oxo-6- phenyloctahydro-1h-pyrrolo[3,4-d]pyrimidin-7a-yl)thiophen-2-yl) benzonitrile (10.1021/JM301039C )
• 4HA5: structure of bace bound to (s)-3-(5-(2-imino-1,4-dimethyl-6- oxohexahydropyrimidin-4-yl)thiophen-3-yl)benzonitrile (10.1021/JM301039C )
• 4HZT: structure-based design of novel dihydroisoquinoline bace-1 inhibitors that do not engage the catalytic aspartates (10.1016/J.BMCL.2013.01.103 )
• 4I0D: design and synthesis of thiophene dihydroisoquinolins as novel bace-1 inhibitors (10.1016/J.BMCL.2013.03.009 )
• 4I0E: design and synthesis of thiophene dihydroisoquinolins as novel bace-1 inhibitors (10.1016/J.BMCL.2013.03.009 )
• 4I0F: design and synthesis of thiophene dihydroisoquinolins as novel bace-1 inhibitors (10.1016/J.BMCL.2013.03.009 )
• 4I0G: design and synthesis of thiophene dihydroisoquinolins as novel bace-1 inhibitors (10.1016/J.BMCL.2013.01.103 )
• 4I0H: spr and structural analysis yield insight towards mechanism of inhibition of bace inhibitors.
• 4I0I: spr and structural analysis yield insight towards mechanism of inhibition of bace inhibitors
• 4I0J: spr and structural analysis yield insight towards mechanism of inhibition of bace inhibitors
• 4I0Z: structure-based design of novel dihydroisoquinoline bace-1 inhibitors that do not engage the catalytic aspartates (10.1016/J.BMCL.2013.01.103 )
• 4I10: structure-based design of novel dihydroisoquinoline bace-1 inhibitors that do not engage the catalytic aspartates (10.1016/J.BMCL.2013.01.103 )
• 4I11: structure-based design of novel dihydroisoquinoline bace-1 inhibitors that do not engage the catalytic aspartates. (10.1016/J.BMCL.2013.01.103 )
• 4I12: design and synthesis of thiophene dihydroisoquinolins as novel bace-1 inhibitors (10.1016/J.BMCL.2013.03.009 )
• 4I1C: design and synthesis of thiophene dihydroisoquinolins as novel bace-1 inhibitors (10.1016/J.BMCL.2013.03.009 )
• 4IVS: crystal structure of bace1 with its inhibitor (10.3390/MOLECULES18055706 )
• 4IVT: crystal structure of bace1 with its inhibitor (10.3390/MOLECULES18055706 )
• 4J0P: crystal structure of bace-1 in complex with 5-cyano-pyridine-2- carboxylic acid [3-((s)-2-amino-4-methyl-5,6-dihydro-4h-[1,3]oxazin- 4-yl)-4-fluoro-phenyl]-amide (10.1021/JM400225M )
• 4J0T: crystal structure of bace-1 in complex with 5-ethoxy-pyridine-2- carboxylic acid [3-((r)-2-amino-5,5-difluoro-4-methyl-5,6-dihydro-4h- [1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide (10.1021/JM400225M )
• 4J0V: crystal structure of bace-1 in complex with 5-cyano-pyridine-2- carboxylic acid [3-((4r,5r)-2-amino-5-fluoro-4-methyl-5,6-dihydro-4h- [1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide (10.1021/JM400225M )
• 4J0Y: crystal structure of bace-1 in complex with 5-cyano-pyridine-2- carboxylic acid [3-((4r,5s)-2-amino-5-fluoro-4-methyl-5,6-dihydro-4h- [1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide (10.1021/JM400225M )
• 4J0Z: crystal structure of bace-1 in complex with 5-cyano-pyridine-2- carboxylic acid [3-((4s,5r)-2-amino-5-fluoro-4-fluoromethyl-5,6- dihydro-4h-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide (10.1021/JM400225M )
• 4J17: crystal structure of bace-1 in complex with 5-cyano-pyridine-2- carboxylic acid [3-((s)-2-amino-4-difluoromethyl-5,6-dihydro-4h-[1, 3]oxazin-4-yl)-4-fluoro-phenyl]-amide (10.1021/JM400225M )
• 4J1C: crystal structure of bace-1 in complex with 5-cyano-pyridine-2- carboxylic acid [3-((s)-2-amino-5,5-difluoro-4-fluoromethyl-5,6- dihydro-4h-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide (10.1021/JM400225M )
• 4J1E: crystal structure of bace-1 in complex with 5-cyano-pyridine-2- carboxylic acid [3-((4s,6s)-2-amino-4-fluoromethyl-6-trifluoromethyl- 5,6-dihydro-4h-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide (10.1021/JM400225M )
• 4J1F: crystal structure of bace-1 in complex with 5-cyano-pyridine-2- carboxylic acid [3-((4s,6s)-2-amino-4-methyl-6-trifluoromethyl-5,6- dihydro-4h-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide (10.1021/JM400225M )
• 4J1H: crystal structure of bace-1 in complex with 5-cyano-pyridine-2- carboxylic acid [3-((4s,6r)-2-amino-4-methyl-6-trifluoromethyl-5,6- dihydro-4h-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide (10.1021/JM400225M )
• 4J1I: crystal structure of bace-1 in complex with 5-cyano-pyridine-2- carboxylic acid [3-((4r,5r,6r)-2-amino-5-fluoro-4-methyl-6- trifluoromethyl-5,6-dihydro-4h-[1,3]oxazin-4-yl)-4-fluoro-phenyl]- amide (10.1021/JM400225M )
• 4J1K: crystal structure of bace-1 in complex with 5-cyano-pyridine-2- carboxylic acid [3-((4r,5r,6s)-2-amino-5-fluoro-4-methyl-6- trifluoromethyl-5,6-dihydro-4h-[1,3]oxazin-4-yl)-4-fluoro-phenyl]- amide (10.1021/JM400225M )
• 4JOO: spirocyclic beta-site amyloid precursor protein cleaving enzyme 1 (bace1) inhibitors (10.1021/JM4002154 )
• 4JP9: spirocyclic beta-site amyloid precursor protein cleaving enzyme 1 (bace1) inhibitors (10.1021/JM4002154 )
• 4JPC: spirocyclic beta-site amyloid precursor protein cleaving enzyme 1 (bace1) inhibitors (10.1021/JM4002154 )
• 4JPE: spirocyclic beta-site amyloid precursor protein cleaving enzyme 1 (bace1) inhibitors (10.1021/JM4002154 )
• 4K8S: hydroxyethylamine-based inhibitors of bace1: p1-p3 macrocyclization can improve potency, selectivity, and cell activity (10.1016/J.BMCL.2013.05.028 )
• 4K9H: bace-1 inhibitor complex (10.1016/J.BMCL.2013.05.028 )
• 4KE0: crystal structure of bace1 in complex with hydroxyethylamine- macrocyclic inhibitor 13 (10.1016/J.BMCL.2013.05.028 )
• 4KE1: crystal structure of bace1 in complex with hydroxyethylamine- macrocyclic inhibitor 19 (10.1016/J.BMCL.2013.05.028 )
• 4L7G: diethylaminosulfur trifluoride-mediated intramolecular cyclization of 2-hydroxy-benzylureas to fused bicyclic aminooxazoline compounds and evaluation of their biochemical activity against beta-secretase-1 (bace1) (10.1016/J.TETLET.2013.07.136 )
• 4L7H: diethylaminosulfur trifluoride-mediated intramolecular cyclization of 2-hydroxy-benzylureas to fused bicyclic aminooxazoline compounds and evaluation of their biochemical activity against beta-secretase-1 (bace-1) (10.1016/J.TETLET.2013.07.136 )
• 4L7J: diethylaminosulfur trifluoride-mediated intramolecular cyclization of 2-hydroxy-benzylureas to fused bicyclic aminooxazoline compounds and evaluation of their biochemical activity against beta-secretase-1 (bace-1) (10.1016/J.TETLET.2013.07.136 )
• 4LC7: aminooxazoline inhibitor of bace-1 (10.1016/J.TETLET.2013.07.136 )
• 4LXA: crystal structure of human beta secretase in complex with compound 11a (10.1016/J.BMCL.2013.07.071 )
• 4LXK: crystal structure of human beta secretase in complex with compound 11d (10.1016/J.BMCL.2013.07.071 )
• 4LXM: crystal structure of human beta secretase in complex with compound 12a (10.1016/J.BMCL.2013.07.071 )
• 4N00: discovery of 7-thp chromans: bace1 inhibitors that reduce a-beta in the cns (10.1021/JM401635N )
• 4PZW: synthesis, characterization and pk/pd studies of a series of spirocyclic pyranochromene bace1 inhibitors (10.1016/J.BMCL.2014.04.012 )
• 4PZX: synthesis, characterization and pk/pd studies of a series of spirocyclic pyranochromene bace1 inhibitors (10.1016/J.BMCL.2014.04.012 )
• 4R5N: 8-tetrahydropyran-2-yl chromans: highly selective beta-site amyloid precursor protein cleaving enzyme 1 (bace1) inhibitors (10.1021/JM5015132 )
• 4R8Y: bace-1 in complex with (r)-4-(2-cyclohexylethyl)-4-(((r)-1-(2- cyclopentylacetyl)pyrrolidin-3-yl)methyl)-1-methyl-5-oxoimidazolidin- 2-iminium (10.1016/J.BMCL.2014.10.006 )
• 4R91: bace-1 in complex with (r)-4-(2-cyclohexylethyl)-4-(((1s,3r)-3- (cyclopentylamino)cyclohexyl)methyl)-1-methyl-5-oxoimidazolidin-2- iminium (10.1016/J.BMCL.2014.10.006 )
• 4R92: bace-1 in complex with (r)-4-(2-cyclohexylethyl)-4-(((1s,3r)-3- (isonicotinamido)cyclohexyl)methyl)-1-methyl-5-oxoimidazolidin-2- iminium (10.1016/J.BMCL.2014.10.006 )
• 4R93: bace-1 in complex with (r)-4-(2-cyclohexylethyl)-1-methyl-5-oxo-4- (((1s,3r)-3-(3-phenylureido)cyclohexyl)methyl)imidazolidin-2-iminium (10.1016/J.BMCL.2014.10.006 )
• 4R95: bace-1 in complex with 2-(((1r,3s)-3-(((r)-4-(2-cyclohexylethyl)-2- iminio-1-methyl-5-oxoimidazolidin-4-yl)methyl)cyclohexyl)amino) quinolin-1-ium (10.1016/J.BMCL.2014.10.006 )
• 4RCD: crystal structure of bace1 in complex with a 2-aminooxazoline 4- azaxanthene inhibitor (10.1021/JM5012676 )